Skip to content
lifestyle.onlygolfnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Moderna, Inc.
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
February 14, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
February 13, 2026
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
February 12, 2026
Dr. David Berman to Join Moderna as Chief Development Officer
January 30, 2026
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
January 29, 2026
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
January 26, 2026
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
January 22, 2026
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
January 5, 2026
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Vaccine Candidate
December 20, 2025
←
Previous Page
1
2
3
4
Next Page
→